THOUSAND OAKS, Calif., June 22, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced it is supporting the further study of AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor, for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy.While intending to support the two Phase 2 clinical trials in ENL and TB set to begin in 2021 by providing study drug, Amgen is interested in partnering these programs with a non-government organziation (NGO) for further development.